Our data show that SSTR2 antagonists not only had 10-fold higher binding to neuroendocrine tumor cells compared to agonists such as 177Lu-DOTA-TOC or -TATE, but also exhibited increased binding to HSC and MPP compared to the agonists. Here, SSTR2 is linked to neuroendocrine neoplasm.